The Biotech Growth Trust (LON:BIOG) Shares Down 0.2% - Here's Why

Key Points

• The Biotech Growth Trust PLC shares fell by 0.2% to GBX 832 ($10.99) during mid-day trading, with a significant increase in trading volume of 146%.
• The company has a market capitalization of £237.69 million and financial ratios including a price-to-earnings ratio of 2.79 and a debt-to-equity ratio of 11.02.
• Insiders have shown confidence in the stock, with Nicola Shepherd and Roger Yates buying a total of 10,500 shares recently at prices around GBX 747 to GBX 771.

The Biotech Growth Trust PLC (LON:BIOG - Get Free Report)'s share price traded down 0.2% during trading on Thursday . The company traded as low as GBX 815.76 ($10.83) and last traded at GBX 832 ($11.05). 375,708 shares traded hands during mid-day trading, an increase of 146% from the average session volume of 152,891 shares. The stock had previously closed at GBX 834 ($11.07).

The Biotech Growth Trust Stock Performance

The company has a market cap of £233.12 million, a PE ratio of 2.74 and a beta of 0.50. The company has a quick ratio of 0.00, a current ratio of 0.59 and a debt-to-equity ratio of 11.02. The company has a 50-day moving average of GBX 758.74 and a 200-day moving average of GBX 767.32.

Insider Buying and Selling at The Biotech Growth Trust

In other The Biotech Growth Trust news, insider Roger Yates bought 10,000 shares of The Biotech Growth Trust stock in a transaction that occurred on Wednesday, June 4th. The stock was acquired at an average cost of GBX 747 ($9.92) per share, for a total transaction of £74,700 ($99,190.01). Also, insider Nicola Shepherd acquired 500 shares of the business's stock in a transaction dated Tuesday, June 10th. The stock was purchased at an average price of GBX 771 ($10.24) per share, with a total value of £3,855 ($5,118.84). Insiders own 0.71% of the company's stock.

The Biotech Growth Trust Company Profile

The Biotech Growth Trust seeks capital appreciation through investment in the worldwide biotechnology industry. In order to achieve its investment objective, the Company invests in a diversified portfolio of shares and related securities in biotechnology companies on a worldwide basis. Performance is measured against the NASDAQ Biotechnology Index (sterling adjusted).